An Oxford University study has found that COVID-19 can cause the brain to shrink, reduce grey matter in the regions that control emotion and memory, and damage areas that control the sense of smell.
Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.
The U.S. Food and Drug Administration granted breakthrough therapy designation to Japanese company Eisai and partner Biogen’s experimental therapy lecanemab for patients with early Alzheimer’s.
U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.
A study published in the Journal of the American Medical Association shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
As pharma companies struggle with developing a treatment for Alzheimer’s disease, researchers continue to find evidence that links the dreaded form of dementia to other medical and health issues. The latest news suggests a potential link between Alzheimer’s and menopause.
What if we could look inside the minds of HCPs to see what is happening there during industry events and interactions?
Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.
Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said.
Researchers have discovered a protein that could help diagnose a degenerative brain disease commonly found in athletes, veterans of military service and others who have experienced brain trauma.